# CheckMate 016 (NCT01472081)

> Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC) (CheckMate 016)

No report yet. It can be ordered.

- Drugs tested: nivolumab plus ipilimumab; nivolumab plus sunitinib; nivolumab plus pazopanib
- Indication: clear-cell metastatic renal cell carcinoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT01472081
- Phase: PHASE1
- Status: COMPLETED
- Sponsor: Bristol-Myers Squibb
- Conditions: Renal Cell Carcinoma; Clear-cell Metastatic Renal Cell Carcinoma
- Interventions: Nivolumab; Pazopanib; Sunitinib; Ipilimumab
- Enrollment: 194
- Primary outcome: Number of Participants With AEs, SAEs, and AEs Leading to Discontinuation

## Indexed commentary on CheckMate 016 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 5
- YouTube: 2

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=checkmate-016-nct01472081